(April 14, 2021, 2:26 PM EDT) -- SAN FRANCISCO — A shareholder sued a biopharmaceutical company and certain of its current and former executive officers in California federal court on April 14, alleging that the defendants issued a series of misrepresentations regarding Phase 3 clinical trial safety and efficacy results for its anemia-treatment drug in violation of federal securities laws....